Rezolute Inc (NAS:RZLT)
$ 4.41 -0.03 (-0.68%) Market Cap: 255.53 Mil Enterprise Value: 149.34 Mil PE Ratio: 0 PB Ratio: 2.15 GF Score: 35/100

Rezolute's Keith Vendola, Ph 2b Initiated, RZ358, Congenital Hyperinsulinism Transcript

Feb 14, 2020 / NTS GMT
Release Date Price: $5 (-14.53%)
Unidentified Participant

Our next presenting company will be Rezolute, and presenting will be Keith Vendola, CFO. Keith?

Keith Vendola
Rezolute, Inc. - CFO & Chief Strategy Officer

Thank you for having me here today. I'm Keith Vendola, the CFO of Rezolute. It's a pleasure to be here. How about we start off with a little story? Imagine you have a child and imagine that for the past several years, you and he have been in and out of hospitals. Together, you've been navigating with a sports team of providers, endocrinologist, pediatricians, surgeons, and social workers, just to name a few.

The doctors have done workups and run blood tests. They've told you that certain genetic mutations within your child's pancreas are causing problems. His beta cells are putting out too much insulin and causing his blood sugar to drop. They've told you to watch this all the time.

Sugar is the main source of energy for his growing brain. If it gets too low, he could have brain damage for life or worse. You hope there's something out there that might help. They say

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot